- Record: found
- Abstract: found
- Article: not found
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Yan Jin
1 ,
Zeruesenay Desta ,
Vered Stearns ,
Bryan Ward ,
Herbert Ho ,
Kyung-Hoon Lee ,
Todd Skaar ,
Anna Maria Storniolo ,
Lang Li ,
Adjei Araba ,
Rebecca Blanchard ,
Anne Nguyen ,
Lynda Ullmer ,
Jill Hayden ,
Suzanne Lemler ,
Richard M Weinshilboum ,
James M Rae ,
Daniel F Hayes ,
David A Flockhart
Jan 05 2005
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely among individuals. Plasma concentrations of the active tamoxifen metabolite endoxifen are associated with the cytochrome P450 (CYP) 2D6 genotype. We examined the effects of concomitant use of selective serotonin reuptake inhibitor antidepressants, which are CYP2D6 enzyme inhibitors commonly prescribed to treat hot flashes in women who take tamoxifen, and genotypes for genes that encode tamoxifen-metabolizing enzymes on plasma concentrations of tamoxifen and its metabolites.